Key Insights

Highlights

Success Rate

99% trial completion (above average)

Published Results

45 trials with published results (36%)

Research Maturity

97 completed trials (78% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.8%

1 terminated out of 124 trials

Success Rate

99.0%

+12.5% vs benchmark

Late-Stage Pipeline

49%

61 trials in Phase 3/4

Results Transparency

46%

45 of 97 completed with results

Key Signals

45 with results99% success

Data Visualizations

Phase Distribution

107Total
Not Applicable (17)
P 1 (14)
P 2 (15)
P 3 (34)
P 4 (27)

Trial Status

Completed97
Unknown15
Active Not Recruiting3
Withdrawn3
Not Yet Recruiting3
Recruiting2

Trial Success Rate

99.0%

Benchmark: 86.5%

Based on 97 completed trials

Clinical Trials (124)

Showing 20 of 20 trials
NCT05010590Phase 4Active Not RecruitingPrimary

Anabolic Therapy in Postmenopausal Osteoporosis

NCT07406685Phase 4Not Yet RecruitingPrimary

The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation

NCT05405725Phase 3CompletedPrimary

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

NCT06577935Phase 2Active Not RecruitingPrimary

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

NCT07365514Phase 1Not Yet RecruitingPrimary

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females

NCT07329543Not Yet Recruiting

AGE Burden and Response to Antiresorptive Therapy in Osteoporosis

NCT06767150Phase 4RecruitingPrimary

StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis

NCT06079476Phase 4CompletedPrimary

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

NCT05630768Phase 4CompletedPrimary

Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

NCT04431960Phase 1CompletedPrimary

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk

NCT05060380Not ApplicableWithdrawn

Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis

NCT02822378Not ApplicableActive Not RecruitingPrimary

Dried Plums and Bone Health in Postmenopausal Women

NCT04934072Phase 3CompletedPrimary

A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis

NCT04591275Phase 3CompletedPrimary

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

NCT04664959Phase 3CompletedPrimary

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

NCT04338529CompletedPrimary

Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation

NCT05087030Phase 3CompletedPrimary

Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

NCT01575834Phase 3CompletedPrimary

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

NCT06457308Not ApplicableCompletedPrimary

Compare the Agility Exercise and Resistance Exercise on Physical Function and Stability in Osteoporotic Women

NCT00092014Phase 3CompletedPrimary

A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)

Scroll to load more

Research Network

Activity Timeline